MOL 4249

Drug Profile

MOL 4249

Alternative Names: MOL4249

Latest Information Update: 29 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Moleculin; University of Texas M. D. Anderson Cancer Center
  • Developer Moleculin; Moleculin Biotech; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antipsoriatics; Small molecules
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cutaneous T cell lymphoma
  • No development reported Plaque psoriasis

Most Recent Events

  • 26 Feb 2016 No recent reports on development identified - Phase-II for Plaque psoriasis in USA (Topical)
  • 15 Oct 2013 Preclinical trials in Cutaneous T-cell lymphoma in USA (Topical)
  • 30 Sep 2013 Phase-IIa clinical trials in mild-to-moderate Plaque psoriasis in USA (Topical) before Sep 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top